The antimicrobial resistance (AMR) crisis was responsible for 1.2 million deaths in 2019 and the mortality rate is predicted to increase to 10 million by 2050, if no action is taken. AMR arises when microbes evolve resistance to antimicrobial drugs such as antibiotics. The major contributor to this crisis is bacteria which can be sub-divided into two groups, based on the presence of an outer membrane. Cell membranes act as a barrier to substances exiting/entering cells and are also present in plant and animal cells. Gram-negative bacteria possess a double membrane; an outer and inner membrane, whilst gram-positive bacteria do not. There are certain components present within the outer membrane that are integral in conferring drug resistance to gram-negative bacteria, making it incredibly difficult to develop new antimicrobials against them. These components can be modified through mutations or replaced all together which prevents antimicrobials from binding to their correct substrates, inhibiting their uptake into bacterial cells. Recently there has been an increased focus placed on the bacterial outer membrane, leading to significant advances in the development of new antimicrobials that are active against gram-negative bacteria. My research showed that newly developed drugs were able to kill or inhibit growth of clinically significant bacteria such as E. coli, Salmonella and many others, in the laboratory and in living animal models. This research is essential for slowing down progression of the AMR crisis; to significantly reduce mortality rates and provide effective treatment for individuals infected with resistant bacteria.